Editorial: Stem Cell Housecleaning
By admin,
Los Angeles Times
| 12. 12. 2007
Even as California's stem cell institute hands out a heartening new round of research grants this week, ethical lapses at the agency show that other items of business are seriously overdue.
One is a blast of public light trained on its grant approval process. That will come as state Controller John Chiang begins an audit of how the California Institute for Regenerative Medicine is spending money and avoiding -- or not avoiding -- conflicts of interest. The other will come up next year, when the three-year moratorium on legislative changes to the stem cell initiative ends. Finally, the Legislature will have the power to amend some of the problems written into Proposition 71 that work against its lofty goal of providing $3 billion for stem cell research.
The need for these and other changes became apparent in recent months when John Reed, president of the Burnham Institute for Medical Research in La Jolla and a member of the stem cell agency's governing board, wrote an appeal to the agency staff asking it to reconsider a rejected application from a researcher...
Related Articles
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Sarah Kliff and Azeen Ghorayshi, The New York Times | 07.15.2024
By Katie LaGrone, WPTV | 06.28.2024
Image by National Cancer Institute from Unsplash
TAMPA, Fla. — A Tampa jury recently found the now-defunct Lung Institute in Tampa guilty of engaging in “deceptive or unfair practices” while it offered customers “valueless” stem cell therapy to treat incurable...
